Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening

Hepatocellular carcinoma is one of the malignancies worldwide with a high mortality rate and an increasing incidence. Molecular Targeted agents are its common first-line treatment. Organoid technology, as a cutting-edge technology, is gradually being applied in the development of therapeutic oncolog...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Cuiying, Gu, Ancheng, Khan, Muhammad, Yao, Xiangcao, Chen, Leping, He, Jiali, Yuan, Fumiao, Wang, Ping, Yang, Yufan, Wei, Yerong, Tang, Fang, Su, Hualong, Chen, Jiamin, Li, Jinxia, Cen, Bohong, Xu, Zhongyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853547/
https://www.ncbi.nlm.nih.gov/pubmed/36686807
http://dx.doi.org/10.3389/fonc.2022.1105454
_version_ 1784872926648991744
author Xie, Cuiying
Gu, Ancheng
Khan, Muhammad
Yao, Xiangcao
Chen, Leping
He, Jiali
Yuan, Fumiao
Wang, Ping
Yang, Yufan
Wei, Yerong
Tang, Fang
Su, Hualong
Chen, Jiamin
Li, Jinxia
Cen, Bohong
Xu, Zhongyuan
author_facet Xie, Cuiying
Gu, Ancheng
Khan, Muhammad
Yao, Xiangcao
Chen, Leping
He, Jiali
Yuan, Fumiao
Wang, Ping
Yang, Yufan
Wei, Yerong
Tang, Fang
Su, Hualong
Chen, Jiamin
Li, Jinxia
Cen, Bohong
Xu, Zhongyuan
author_sort Xie, Cuiying
collection PubMed
description Hepatocellular carcinoma is one of the malignancies worldwide with a high mortality rate and an increasing incidence. Molecular Targeted agents are its common first-line treatment. Organoid technology, as a cutting-edge technology, is gradually being applied in the development of therapeutic oncology. Organoid models can be used to perform sensitivity screening of targeted drugs to facilitate the development of innovative therapeutic agents for the treatment of hepatocellular carcinoma. The purpose of this review is to provide an overview of the opportunities and challenges of hepatocellular carcinoma organoids in targeted drug sensitivity testing as well as a future outlook.
format Online
Article
Text
id pubmed-9853547
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-98535472023-01-21 Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening Xie, Cuiying Gu, Ancheng Khan, Muhammad Yao, Xiangcao Chen, Leping He, Jiali Yuan, Fumiao Wang, Ping Yang, Yufan Wei, Yerong Tang, Fang Su, Hualong Chen, Jiamin Li, Jinxia Cen, Bohong Xu, Zhongyuan Front Oncol Oncology Hepatocellular carcinoma is one of the malignancies worldwide with a high mortality rate and an increasing incidence. Molecular Targeted agents are its common first-line treatment. Organoid technology, as a cutting-edge technology, is gradually being applied in the development of therapeutic oncology. Organoid models can be used to perform sensitivity screening of targeted drugs to facilitate the development of innovative therapeutic agents for the treatment of hepatocellular carcinoma. The purpose of this review is to provide an overview of the opportunities and challenges of hepatocellular carcinoma organoids in targeted drug sensitivity testing as well as a future outlook. Frontiers Media S.A. 2023-01-06 /pmc/articles/PMC9853547/ /pubmed/36686807 http://dx.doi.org/10.3389/fonc.2022.1105454 Text en Copyright © 2023 Xie, Gu, Khan, Yao, Chen, He, Yuan, Wang, Yang, Wei, Tang, Su, Chen, Li, Cen and Xu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xie, Cuiying
Gu, Ancheng
Khan, Muhammad
Yao, Xiangcao
Chen, Leping
He, Jiali
Yuan, Fumiao
Wang, Ping
Yang, Yufan
Wei, Yerong
Tang, Fang
Su, Hualong
Chen, Jiamin
Li, Jinxia
Cen, Bohong
Xu, Zhongyuan
Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening
title Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening
title_full Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening
title_fullStr Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening
title_full_unstemmed Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening
title_short Opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening
title_sort opportunities and challenges of hepatocellular carcinoma organoids for targeted drugs sensitivity screening
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9853547/
https://www.ncbi.nlm.nih.gov/pubmed/36686807
http://dx.doi.org/10.3389/fonc.2022.1105454
work_keys_str_mv AT xiecuiying opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT guancheng opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT khanmuhammad opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT yaoxiangcao opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT chenleping opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT hejiali opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT yuanfumiao opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT wangping opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT yangyufan opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT weiyerong opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT tangfang opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT suhualong opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT chenjiamin opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT lijinxia opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT cenbohong opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening
AT xuzhongyuan opportunitiesandchallengesofhepatocellularcarcinomaorganoidsfortargeteddrugssensitivityscreening

Ejemplares similares